Why this article exists

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide (sequence GEPPPGKPADDAGLV, molecular weight 1,419 Da) derived from a larger protein first isolated from human gastric juice. It is marketed online as a healing agent for chronic musculoskeletal injury, sold variously as subcutaneous injectables, plain capsules, and enteric-coated tablets, and surrounded by a thicket of consumer claims that frequently outrun the published evidence.

The goal of this article is not to sell or dismiss. It is to take the most commonly repeated BPC-157 claims — torn tendons, cut ligaments, severed nerves, spinal cord injury, corneal perforation, bone defects, crushed muscle, stroke, inflammatory bowel disease, and alcohol-induced gastric injury — link each one to the actual published study behind it, summarize what that study did and found, and then step back to evaluate the overall landscape. Where the science is strong, that is stated. Where it is weak, missing, or extrapolated, that is stated too.

The headline claims, line by line, study by study

Below is the list of claims most commonly made for BPC-157, each linked to the cited source. Each entry is then expanded with the study design, model organism, dose, route, and reported outcome.

• → Torn tendons: REATTACHED — Krivic et al., 2006
• → Cut ligaments: HEALED — Cerovecki et al., 2010
• → Cut nerves: RECONNECTED — Gjurasin et al., 2010
• → Crushed spine: PROTECTED — Perovic et al., 2019
• → Hole in eye: SEALED — Masnec et al., 2015
• → Missing bone: FILLED IN — Sebecic et al., 1999
• → Crushed muscle: HEALED — addressed across the broader tendon-to-bone-to-muscle program, summarized in Vasireddi et al., 2025
• → Stroke brain: PROTECTED — Vukojević et al., 2020
• → Inflamed colon: HEALED — Sikiric et al., 2012
• → Alcohol stomach: SHIELDED — Gojkovic et al., 2021

1. Torn tendons — tendon-to-bone reattachment

The Krivic et al. (2006) study examined the most clinically intractable problem in tendon orthopedics: the tendon-to-bone interface, the site where rotator cuff repairs and similar reattachment surgeries frequently fail. Using a rat model, the investigators surgically damaged the tendon-bone attachment and showed that corticosteroid administration (6α-methylprednisolone, the same compound commonly injected into injured shoulders and knees) consistently worsened healing, while BPC-157 substantially reduced that corticosteroid-induced healing impairment. The broader tendon program extends further back: Staresinic et al. (2003) demonstrated accelerated healing of transected rat Achilles tendon, and Chang et al. (2011) showed increased tendon fibroblast outgrowth in vitro — the cell population responsible for rebuilding the collagen cable of the tendon itself.

In aggregate, the tendon evidence shows BPC-157 not only promotes healing but actively reverses the healing-suppression effect of corticosteroids, which is a clinically meaningful distinction given how often cortisone injections are used in chronic tendinopathy.

2. Cut ligaments — medial collateral ligament healing

Cerovecki et al. (2010) surgically transected the medial collateral ligament (MCL) in rats and tracked healing over 90 days. BPC-157 was administered via two routes: intraperitoneal injection and per-oral delivery (dissolved in drinking water at 0.16 µg/ml, approximately 12 ml per rat per day). Both routes produced consistent functional, biomechanical, macroscopic, and histological improvements compared with controls. The ligament did not merely scar back together; the healed tissue showed better-organized architecture and superior mechanical strength.

This study is particularly important for the oral-versus-injection debate because the oral route — continuous low-dose exposure in drinking water — was effective. However, the dosing regimen (continuous exposure over 24 hours for 90 days) is not directly comparable to once-daily oral capsule dosing in humans.

3. Cut nerves — peripheral nerve regeneration

Gjurasin et al. (2010) transected the rat sciatic nerve — the major peripheral nerve of the lower limb, the injury that produces foot drop and chronic neuropathic pain in humans. BPC-157 was administered at 10 µg and 10 ng/kg body weight. Treated animals displayed faster axonal regeneration, with histomorphometric improvements including better-organized neural fascicles, a homogeneous regeneration pattern, increased density and caliber of regenerating fibers, evidence of epineural and perineural regeneration, uniform target orientation of regrowing fibers, and a higher ratio of neural tissue to scar. Peripheral nerves typically regenerate poorly and tend to form disorganized neuromas; BPC-157 shifted the regenerative outcome toward organized, target-directed regrowth.

4. Crushed spine — spinal cord injury

Perovic et al. (2019) used a rat spinal cord injury model and reported that BPC-157 "can improve the healing course of spinal cord injury and lead to functional recovery." A 2022 follow-up by the same group elaborated the mechanism: BPC-157 rapidly attenuated spinal cord hematoma and swelling in acutely injured rats, and appeared to counteract axonal and neuronal necrosis, demyelination, and the secondary injury cascade. The secondary injury — the wave of inflammation, edema, and progressive cell death that spreads outward from the original impact site over hours to days — is the process that converts partial spinal injuries into complete ones. Interrupting that cascade is the central pharmacological target in spinal cord injury research.

5. Hole in eye — perforating corneal injury

Masnec et al. (2015) used a rat model of perforating corneal injury — a puncture wound through the clear avascular front of the eye. In untreated controls, new blood vessels grew from the limbus into the penetrated area, destroying corneal transparency and producing permanent vision loss. BPC-157 treatment was associated with "rapid regaining of corneal transparency" and prevention of that destructive neovascularization. The cornea is normally avascular precisely to maintain optical clarity; BPC-157 appeared to respect that architecture while sealing the wound. Earlier dose-dependent corneal epithelial healing was reported by Lazic et al. (2005) and Gabric et al. (2003).

6. Missing bone — segmental bone defects

Sebecic et al. (1999) created segmental bone defects in an animal model — actual gaps in bone that do not heal spontaneously and that in human orthopedics typically require bone grafting. BPC-157 "significantly improved the healing of segmental bone defects," with radiographic assessment demonstrating increased callus surface (the new bone scaffold the body deposits to bridge a defect) and improved overall healing. This was one of the earliest demonstrations that a peptide — rather than a stem cell, recombinant growth factor, or bone morphogenetic protein — could fill a structural bone gap.

7. Crushed muscle — musculoskeletal program

BPC-157's musculoskeletal program covers the entire tendon-to-bone-to-muscle continuum, including the myotendinous junction (where muscle transitions to tendon) and the osteotendinous junction (where tendon inserts into bone). The systematic review by Vasireddi et al. (2025) pooled the preclinical literature and reported that BPC-157 consistently improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injury models. Crushed-muscle models specifically showed reduced secondary tissue damage and faster restoration of contractile function.

8. Stroke brain — hippocampal ischemia/reperfusion

Vukojević et al. (2020) used a rat model of hippocampal ischemia/reperfusion, the pathophysiological mechanism of ischemic stroke, in which a clot starves brain tissue of oxygen and subsequent reperfusion itself causes additional injury. BPC-157 "effectively ameliorated ischemia/reperfusion injuries," leading the authors to suggest it "may provide a novel therapeutic solution for stroke." A 2021 follow-up by the same group showed BPC-157 promoted full functional recovery, with measurable improvements on the Morris water maze (a spatial memory task) and the inclined beam-walking test (a motor-coordination task). The hippocampus is among the brain regions most vulnerable to ischemic injury and most central to memory formation; protecting it is the dominant target in stroke recovery research.

9. Inflamed colon — inflammatory bowel disease

Sikiric et al. (2012) is among the most clinically significant papers in the BPC-157 literature because it bridges preclinical work to human data. The peptide was described as "stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects," and had already been tested in a Phase II clinical trial for inflammatory bowel disease under the drug code PL 14736, with a reported safe profile and a "particular wound healing effect." This is the closest BPC-157 has come to becoming an approved human drug. Related work (Klicek et al., 2013) showed BPC-157 simultaneously healed cysteamine-induced colitis and colon-colon anastomosis, while controls healed neither.

10. Alcohol stomach — gastric mucosal cytoprotection

Gojkovic et al. (2021) used Robert's intragastric alcohol-induced gastric lesion model — the standard assay for studying ethanol damage to the stomach lining. The investigators redefined and refined the model and used it to characterize the cytoprotective effects of BPC-157, which shielded the gastric mucosa from ethanol-induced injury. This builds on a body of work stretching back two decades (Blagaic et al., 2004; Prkacin et al., 2001; Boban-Blagaic et al., 2006) demonstrating that BPC-157 opposes the strongest presentations of acute alcohol intoxication, including sustained ethanol anesthesia and complete loss of righting reflex. BPC-157 was originally characterized as a "gastric pentadecapeptide" — a stomach-protecting compound — so this remains its most mechanistically established domain.

Making sense of the landscape: injection vs. oral, animal vs. human, supplement vs. drug

The BPC-157 evidence base is genuinely difficult to navigate because it sits at the intersection of several confounds: nearly all efficacy data is animal-derived; the human data is extremely limited; the peptide is sold both as a subcutaneous injectable and as oral formulations with competing absorption claims; and the regulatory status varies by jurisdiction. The following sections unpack each confound.

Mechanism of action

BPC-157 acts through several overlapping pathways. It upregulates VEGFR2 (vascular endothelial growth factor receptor 2), driving angiogenesis — the formation of new blood vessels from existing vasculature. It boosts nitric oxide synthesis via the Akt-eNOS axis, which supports vascular tone and endothelial function. It engages ERK1/2 signaling, facilitating endothelial and muscle repair. And it reduces inflammatory cytokine activity. The net effect is enhanced angiogenesis, fibroblast activation (the cells that synthesize collagen and rebuild connective tissue), and neuromuscular stabilization, with particular activity in poorly vascularized tissues such as tendons and myotendinous junctions — the exact tissues that heal poorly precisely because of limited blood supply.

The animal-versus-human evidence gap

This is the central caveat in the entire BPC-157 literature. The 2025 systematic review by Vasireddi and colleagues, published in HSS Journal (the journal of the Hospital for Special Surgery), screened 544 articles and included 36 studies. Of those 36, 35 were preclinical (animal) studies and exactly 1 was clinical (human). The 2025 narrative review by McGuire et al., published in Current Reviews in Musculoskeletal Medicine, identified only three pilot human studies in total:

• An intraarticular knee injection study for chronic knee pain, in which 7 of 12 patients reported relief lasting more than 6 months.
• An interstitial cystitis (bladder pain syndrome) pilot study.
• An intravenous safety and pharmacokinetics study establishing tolerability and disposition.

That is the entirety of the published human efficacy and safety data as of mid-2025. Three small pilots. No large randomized controlled trials. No Phase III. The Phase II IBD trial (PL 14736) reported a clean safety profile but did not advance to an approved drug.

The honest reading of the evidence is therefore: BPC-157 has been shown to produce the listed healing effects in animals, the mechanism is biologically plausible for similar effects in humans, but efficacy in humans has not been established. This distinction matters and is frequently elided in consumer-facing marketing.

The injection-versus-oral question

Most of the animal efficacy studies administered BPC-157 via intraperitoneal injection or via continuous oral delivery in drinking water over weeks. Neither regimen directly translates to a once-daily oral capsule or tablet in humans.

The peptide's full research name — "stable gastric pentadecapeptide BPC 157" — reflects the fact that it survives exposure to gastric juice, a property the originating Sikiric laboratory in Zagreb has characterized across 30 years of work. This means the common marketing claim that stomach acid "destroys" plain BPC-157 capsules is, strictly speaking, not accurate at the molecular level; the peptide is unusually acid-stable for a peptide.

However, surviving gastric exposure is not the same as achieving systemic absorption. The original clinical development (PL 14736) targeted gastrointestinal conditions — ulcers, oral mucositis, inflammatory bowel disease — in which BPC-157 acts locally on the gut mucosa and does not need to reach the systemic circulation. The musculoskeletal effects observed in animal studies require the peptide to reach injured tissues systemically. Once-daily oral capsule dosing does not reproduce the continuous-exposure oral regimen used in the ligament study, and the absorption fraction from a single oral dose in humans has not been formally characterized.

Enteric-coated oral formulations are designed to bypass gastric release and deliver the peptide to the small intestine, where absorption into the systemic circulation is theoretically more favorable. This design rationale is plausible and is consistent with general pharmaceutical principles, but there is currently no published human pharmacokinetic study directly comparing enteric-coated BPC-157 tablets to plain capsules. The most thorough pharmacokinetic work to date — He et al. (2022) — proposed a 200 µg/person/day clinical dose based on body-surface-area conversion from rat data, but that work was based on injectable/IV formulation rather than oral tablets.

Injection route

The subcutaneous injection route, commonly used in the sports-medicine and consumer peptide communities, maximizes bioavailability by bypassing the gut entirely and delivering the peptide near the injury site. The arguments against self-administered injection are: (a) most consumer injectable BPC-157 is sold as an unregulated "research chemical" rather than a pharmacy-compounded drug, introducing risks of contamination, mis-dosing, and identity misrepresentation; (b) the animal efficacy studies predominantly used intraperitoneal injection, which is not pharmacokinetically equivalent to subcutaneous injection; and (c) the one published human knee study used intraarticular injection administered by a clinician, not self-injected consumer product. Injectable BPC-157, when used clinically, is generally obtained through a compounding pharmacy with a prescription.

Safety, regulatory status, and doping

Three facts bear on any decision to use BPC-157:

1. FDA approval. BPC-157 is not approved by the U.S. Food and Drug Administration for any condition. It is sold in a regulatory gray zone as a "research chemical" or "dietary supplement." The Phase II IBD trial (PL 14736) was conducted in Europe and did not result in an approved drug to date.
2. Preclinical safety. The systematic review reported no adverse effects across multiple organ systems in animal studies. The LD1 (lethal dose for 1% of test animals) "has not been achieved," meaning investigators were unable to establish a lethal threshold at the doses tested. The Phase II human trial reported a clean safety profile, and the three human pilot studies reported no adverse effects. This safety signal is reassuring but is not equivalent to large-scale, long-term human safety data, which does not exist.
3. WADA Prohibited List. BPC-157 is on the World Anti-Doping Agency's Prohibited List and is banned in professional and sanctioned sports. Athletes subject to WADA, USADA, NCAA, or Olympic testing cannot use it. The 2025 systematic review explicitly recommends that clinicians counsel athletes on this point.

The reported plasma half-life is short — under 30 minutes after IV administration — with hepatic metabolism and renal clearance. The practical implication is that dosing regimen and formulation design (e.g., enteric coating to delay release) materially affect the duration of systemic exposure, although the relationship between plasma pharmacokinetics and tissue-level healing effects has not been formally established.

Bottom line: if you wanted to act on this today, what can we do

For a reader evaluating BPC-157 as a potential intervention for a chronic injury, the following evidence-based action framework applies:

1. Establish an accurate diagnosis first. BPC-157 is proposed to promote healing, not to mask pain. Before considering any peptide therapy, obtain appropriate imaging (MRI, diagnostic ultrasound) and a clear diagnosis from a qualified clinician. Treating an undefined problem with an unapproved peptide is not appropriate.
2. Check doping status. If subject to WADA, USADA, NCAA, or Olympic drug testing, BPC-157 is prohibited and its use carries sanction risk. The ban applies regardless of source or route of administration.
3. Understand the evidence tier. As of mid-2025, BPC-157 has robust and consistent preclinical evidence across multiple tissue types (35 of 36 included studies in the 2025 systematic review were preclinical), biological plausibility via defined mechanisms, and only three small human pilot studies. Human efficacy has not been established. Any use is therefore off-label, experimental, and undertaken on the basis of preclinical evidence rather than proven clinical efficacy.
4. Select route and source carefully. Oral enteric-coated formulations are designed to address the systemic-absorption problem but have not been formally compared to plain capsules in published human pharmacokinetic studies. Subcutaneous injection offers higher bioavailability but should use product obtained through a compounding pharmacy with a prescription, not unregulated "research chemical" sources. Injection should ideally be conducted with clinical guidance.
5. Dose and duration. He et al. (2022) proposed 200 µg/person/day as a clinical dose based on body-surface-area conversion from rat data; commercial oral formulations commonly supply 500 µg per dose. The ligament healing study dosed rats continuously for 90 days. Realistically, a minimum trial of 4–8 weeks is required before judging response; shorter trials are uninformative given the biology of tissue remodeling.
6. Maintain concurrent rehabilitation. BPC-157 is proposed to create a permissive healing environment; it does not substitute for the mechanical loading, mobilization, and strengthening that signal new tissue to organize along functional lines. Concurrent physiotherapy is expected to be necessary for meaningful outcome.
7. Define and track a measurable outcome. Before initiating use, record baseline pain (0–10 scale), range of motion, and one or more specific functional limitations (e.g., inability to lift overhead, sitting tolerance). Re-assess at 4 and 8 weeks. If no measurable improvement occurs, the diagnosis, dose, route, or appropriateness of the intervention should be reconsidered rather than escalating dose or extending duration.
8. Consult a qualified clinician. Most physicians are not familiar with peptide therapeutics. Sports-medicine, functional-medicine, and orthobiologics clinicians are more likely to have relevant expertise. They can evaluate contraindications, assess drug interactions, and — where appropriate — prescribe pharmacy-compounded BPC-157 in place of unregulated consumer products.

The current state of the evidence supports BPC-157 as one of the most consistently effective healing agents in preclinical models, with a defined molecular mechanism, an apparently favorable safety signal, a small but real human pilot literature, no FDA approval, a WADA prohibition, and a confusing oral-versus-injection delivery landscape. The honest summary is that it is a promising investigational peptide, not a validated therapy. Anyone using it is, by definition, participating in an uncontrolled experiment on themselves, and should do so with eyes open and ideally with clinical supervision.

Sources

• Krivic A, et al. Promoted tendon-to-bone healing and opposed methylprednisolone-induced healing aggravation by BPC 157. PubMed PMID: 16583442 (tendon-to-bone, rat, 2006).
• Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected Achilles tendon. PubMed PMID: 14554208 (Achilles tendon, rat, 2003).
• Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon fibroblast outgrowth. PubMed PMID: 21030672 (tendon fibroblast mechanism, 2011).
• Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. PubMed PMID: 20225319 (MCL transection, oral + IP, 90 days, 2010).
• Gjurasin M, et al. Peptide therapy with pentadecapeptide BPC 157 in transected rat sciatic nerve. PubMed PMID: 19903499 (peripheral nerve, rat, 2010).
• Perovic D, et al. Stable gastric pentadecapeptide BPC 157 can improve spinal cord injury healing in rats. PubMed PMID: 31266512 / PMC PMC6604284 (spinal cord, rat, 2019).
• Masnec S, et al. Perforating corneal injury in rat and pentadecapeptide BPC 157. PubMed PMID: 25912999 (cornea, rat, 2015).
• Sebecic B, et al. Osteogenic effect of a gastric pentadecapeptide BPC-157 on segmental bone defect healing. PubMed PMID: 10071911 (bone defect, 1999).
• Vukojević J, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries. PMC PMC7428500 (stroke model, rat, 2020).
• Vukojević J, et al. Pentadecapeptide BPC 157 and the central nervous system. PMC PMC8504390 (CNS functional recovery review, 2021).
• Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 — focus on ulcerative colitis. PubMed PMID: 22300085 (colon/IBD, Phase II PL 14736, 2012).
• Klicek R, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine colitis and colon-colon anastomosis. PubMed PMID: 24304574 (colon anastomosis, rat, 2013).
• Gojkovic S, et al. Robert's intragastric alcohol-induced gastric lesion model and BPC 157 cytoprotection. PubMed PMID: 34680419 (alcohol gastric injury, rat, 2021).
• Blagaic AB, et al. The influence of gastric pentadecapeptide BPC 157 on acute and chronic alcohol-induced lesions. PubMed PMID: 15381050 (alcohol stomach/liver, 2004).
• Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. PubMed PMID: 29998800 (angiogenesis mechanism review, 2018).
• Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMC PMC12313605 (systematic review, 36 studies, 35 preclinical + 1 clinical).
• McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. PMC PMC12446177 (narrative review, 3 human pilot studies).
• He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of BPC-157. PMC PMC9794587 (proposed 200 µg/person/day human dose, 2022).
• Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 — Robert's stomach lesion model and cytoprotection. Gut and Liver review, 2020 (gastric cytoprotection).
• Gwyer D, et al. Gastric pentadecapeptide BPC — review of healing effects. 2019 (overview across injury types).

Disclaimer: This article is a lay summary of published peer-reviewed research and is not medical advice. BPC-157 is not approved by the U.S. Food and Drug Administration for any condition and is on the World Anti-Doping Agency Prohibited List. Consult a qualified clinician before considering any peptide therapy, particularly in the setting of chronic medication use, pregnancy, chronic illness, or participation in drug-tested sport.